ArticleACS omega2026
Expiration Date of Extemporaneous Pyrimethamine Formulations for Treating Congenital Toxoplasmosis: Physicochemical and Microbiological Evaluation.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the stability of extemporaneous pyrimethamine oral suspensions prepared from commercial tablets using 85% sucrose or 70% sorbitol as vehicles. A validated HPLC method was employed to quantify pyrimethamine and assess its chemical stability. Physicochemical parameters including macroscopic appearance, pH, particle size, and drug content were monitored for 90 days at 5 and 25 °C. Both formulations maintained acceptable pH values and pyrimethamine content within pharmacopeial limits. Particle size increased over time, likely due to aggregation, while appearance remained unchanged for up to 45 days. Microbiological assessments showed that microorganisms remained within acceptable limits, with no objectionable microorganisms detected. Overall, both suspensions demonstrated chemical and microbiological stability for up to 45 days (Suspension S) and 60 days (Suspension X) under both storage conditions. These results support the preparation of cost-effective pyrimethamine formulations for treating congenital toxoplasmosis in pediatric patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.